Pivotal phase III trial of darinaparsin in patients with peripheral T-cell lymphoma (PTCL) in Asia

Trial Profile

Pivotal phase III trial of darinaparsin in patients with peripheral T-cell lymphoma (PTCL) in Asia

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2014

At a glance

  • Drugs Darinaparsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Solasia Pharma
  • Most Recent Events

    • 17 Sep 2014 New trial record
    • 31 Jul 2014 This pivotal trial is expected to be initiated in Asia in early 2015, according to a ZIOPHARM Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top